RxDoctor Payments Data

Lisa Piper, MD

Family Medicine · Lagrange, INNPI 1063447753

Payments from drug & device makers

$7,021in general payments, 2019–2025

Across 24 payments — averaging $292.56 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • GE HealthCare$7K
  • Novo Nordisk$113
  • Tersera Therapeutics LLC$46
  • Amgen$44
  • Novartis$37
  • Pfizer$31
  • plus $79 from 4 others

What the payments were for

  • Consulting fees$5,55979%
  • Speaking & faculty fees$1,11216%
  • Food & beverage$3515%

General payments by program year

19
20
23
24

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
GE HealthCare2$6,671
Novo Nordisk8$113
Tersera Therapeutics LLC2$46
Amgen2$44
Novartis2$37
Pfizer2$31
GSK2$26
AstraZeneca2$25
AbbVie1$16
Abbott1$13

How this compares

$7,021 in reported general payments places this provider in the 90th percentile of 2,709 family medicine providers in Indiana.

See all family medicine providers in Indiana

Medicare billing

Part B allowed, 2024
$52,574
Medicare patients
167
Services billed
953

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
Humira(Cf) PenAdalimumab13$167,310
OzempicSemaglutide117$158,611
MounjaroTirzepatide59$68,346
EliquisApixaban57$51,936
Trelegy ElliptaFluticasone/Umeclidin/Vilanter48$44,583
Anoro ElliptaUmeclidinium Brm/Vilanterol Tr60$28,635
TrulicityDulaglutide23$27,580
Basaglar Kwikpen U-100Insulin Glargine,hum.Rec.Anlog28$22,342
JardianceEmpagliflozin22$19,736
FarxigaDapagliflozin Propanediol15$17,403
Lantus SolostarInsulin Glargine,hum.Rec.Anlog72$17,365
XareltoRivaroxaban15$16,232
Spiriva RespimatTiotropium Bromide16$11,372
Emgality PenGalcanezumab-Gnlm11$7,751
Humalog Kwikpen U-100Insulin Lispro33$7,416

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$113$158,611117 claims
GSKTrelegy Ellipta, Anoro Ellipta, Breo Ellipta$26$79,441119 claims
PfizerEliquis$31$51,93657 claims
AstraZenecaFarxiga$25$17,40315 claims
AbbVieSynthroid$16$2,40030 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 2,709 family medicine providers in Indiana.

Other family medicine in Lagrange

See the full list for Indiana

Where these figures come from

Is this you, or does something look wrong? →